US20070060755A1 - Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates - Google Patents

Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates Download PDF

Info

Publication number
US20070060755A1
US20070060755A1 US11/600,673 US60067306A US2007060755A1 US 20070060755 A1 US20070060755 A1 US 20070060755A1 US 60067306 A US60067306 A US 60067306A US 2007060755 A1 US2007060755 A1 US 2007060755A1
Authority
US
United States
Prior art keywords
carbon atoms
imidazo
group
quinoline
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/600,673
Inventor
Valeriano Merli
Silvia Mantovani
Stefano Bianchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Works PLC
Original Assignee
Teva Pharmaceutical Works PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Works PLC filed Critical Teva Pharmaceutical Works PLC
Priority to US11/600,673 priority Critical patent/US20070060755A1/en
Publication of US20070060755A1 publication Critical patent/US20070060755A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention provides 1H-imidazo (4,5-c) quinoline-4-phthalimide intermediates useful in the synthesis of 1H-imidazo (4,5-c) quinoline-4-amines, particularly Imiquimod. The invention further provides a method for making the intermediates and a method for making 1H-imidazo (4,5-c) quinoline-4-amines via the intermediates.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • This application is a division of U.S. patent application Ser. No. 11/023,021, filed Dec. 23, 2004, which is a division of U.S. patent application Ser. No. 10/626,036, filed Jul. 23, 2003, which claims the benefit of U.S. Provisional Application No. 60/397,607, filed Jul. 23, 2002, the contents of which is incorporated herein.
  • FIELD OF THE INVENTION
  • The present invention relates to a process for the synthesis of 1H-imidazo [4,5-c] quinoline 4-phthalimide intermediates useful in preparing 1H-imidazo [4,5-c] quinoline 4-amines, a process for preparing 1H-imidazo [4,5-c] quinoline 4-amines using such intermediates; and, to the 1H-imidazo[4,5-c] quinoline 4-phthalimide intermediates. More particularly, the present invention relates to a novel process for the preparation of 1-isobutyl-1H-imidazo [4,5-c] quinoline 4-amine (Imiquimod) by introducing an amino group in the 4 position of 1-isobutyl-1H-imidazo [4,5-c] quinoline-4-amine via a 1-isobutyl-1H-imidazo [4,5-c] quinoline 4-phthalimide intermediate, and to the 1-isobutyl-1H-imidazo[4,5-c] quinoline 4-phthalimide intermediate.
  • BACKGROUND OF THE INVENTION
  • Imiquimod, 1-isobutyl-1H-imidazo [4,5-c] quinolin-4-amine, is an immune response modifier, useful for treating viral infections, such as genital warts. Imiquimod is disclosed in U.S. Pat. Nos. 4,689,338 and 5,238,944 and has the structure:
    Figure US20070060755A1-20070315-C00001
  • Several methods are known in the art for making 1H-imidazo [4,5-c]quinoline 4-amines, including Imiquimod. The amino group in the 4 position has been introduced in essentially three ways: The first is by nucleophilic substitution of a leaving group, e.g., Cl, triflate, etc., with ammonia, dibenzylamine or an azido group; the second is by reacting 1-isobutyl-1H-imidazo [4,5-c] quinoline-N-oxide with ammonium hydroxide or ammonium salts in the presence of tosyl chloride at 0-5° C.; and the third is by reacting 1-isobutyl-1H-imidazo[4,5-c]quinoline-N-oxide with benzoyl isocyanate.
  • Nucleophilic substitution reactions are disclosed in, for example, WO 97/48704, WO 92/06093, U.S. Pat. Nos. 5,395,937, 5,756,747, 4,988,815, 5,602,256, 5,578,727, 4,698,348, and 4,689,388, European patents EP 145340, EP 0385630, and EP 310950, and JP 04193866. Specifically, in WO 97/48704 the amino group is introduced by reaction of a 4-chloro derivative with sodium azide to obtain a tetrazole moiety. Reaction of the tetrazole moiety with triphenylphosphine gives the 4-amino derivative. In U.S. Pat. No. 5,395,937, a 4-triflate derivative is reacted with dibenzylamine. The catalytic reduction of the 4-dibenzylamino derivative places an amino group in the 4-position. U.S. Pat. No. 5,756,474, discloses a nucleophilic substitution with ammonia on a 4-chloro derivative, obtained by isomerization of 1-isobutyl-1H-imidazo[4,5-c]quinoline-N-oxide to the 4-hydroxy derivative, followed by reaction with POCl3. The following patents all disclose a nucleophilic substitution of 1-isobutyl-1H-imidazo[4,5-c]quinoline-4-chloro with ammonia at high temperature and pressure: U.S. Pat. Nos. 4,988,815, 5,602,256, 5,578,727, 4,698,348, 4,689,388, EP 145340, JP 04193866, EP 0385630, and EP 310950.
  • WO 92/06093 discloses reacting 1-isobutyl-1H-imidazo [4,5-c] quinoline-N-oxide with ammonium hydroxide or ammonium salts in the presence of tosyl chloride at 0-5° C.
  • WO 92/15581 discloses reacting 1-isobutyl-1H -imidazo[4,5-c]quinoline-N-oxide with benzoyl isocyanate.
  • However, a need exists in the art for making 1H-imidazo [4,5-c] quinoline 4-amines, especially Imiquimod, in high purity and high yield and which does not require high temperature or pressure.
  • SUMMARY OF THE INVENTION
  • In one aspect, the present invention is directed to a compound of formula (II):
    Figure US20070060755A1-20070315-C00002

    wherein
      • R1 is selected from the group consisting of: hydrogen; a straight or branched chain alkyl of one to about 10 carbon atoms, optionally substituted with a substituent selected from the group consisting of lower alkyl, cycloalkyl of 3 to about 6 carbon atoms, wherein said cycloalkyl is optionally substituted with a lower alkyl group; straight or branched chain alkenyl of 2 to about 10 carbon atoms, wherein the olefinic unsaturation in the alkenyl group is at least one carbon atom removed from the 1-nitrogen, and wherein the straight or branched chain alkyl is optionally substituted with a substituent selected from the group consisting of lower alkyl, cycloalkyl of 3 to about 6 carbon atoms, wherein said cycloalkyl is optionally substituted with a lower alkyl group; hydroxyalkyl of one to about six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or benzoyloxy and the alkyl moiety contains one to about six carbon atoms; benzyl; (phenyl)ethyl; and phenyl, wherein said benzyl, (phenyl)ethyl and phenyl substituents are optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain more than 6 carbon atoms;
      • R2 is selected from the group consisting of: hydrogen; straight or branched chain alkyl containing one to about eight carbon atoms; benzyl; (phenyl)ethyl; and phenyl, wherein said benzyl, (phenyl)ethyl and phenyl substituents are optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain more than 6 carbon atoms;
      • R is independently selected from the group consisting of: alkoxy of one to about four carbon atoms; alkyl of one to about four carbon atoms; and halogen; and
      • n is an integer from 0 to 2, with the proviso that if n is 2, then said groups together contain no more than 6 carbon atoms.
  • In a preferred embodiment, R, is isobutyl, R, is hydrogen, n is 0.
  • In another aspect, the present invention is directed to a process for preparing a 1H-imidazo[4,5-c] quinoline 4-phthalimide of formula (II) comprising reacting a compound of formula (III) with phthalimide in a suitable organic solvent, wherein R, R1, R2, and n are defined above.
    Figure US20070060755A1-20070315-C00003
  • In another aspect, the present invention is directed to a process for preparing a compound of formula (I):
    Figure US20070060755A1-20070315-C00004

    comprising reacting a compound of formula (II) with hydrazine hydrate in a suitable solvent, wherein R, R1, R2, and n are defined above.
  • These and other aspects of the present invention will now be described in more detail with reference to the following detailed description of the invention.
  • DETAILED DESCRIPTION OF THE INVENTION
  • In one aspect, the present invention is directed to a process for preparing 1H-imidazo[4,5-c]quinoline-4-amines of formula (I). The preferred 1H-imidazo[4,5-c] quinoline-4-amine is Imiquimod. However, the inventive process can be used to prepare any compound within the scope of formula (I), including those disclosed in U.S. Pat. Nos. 5,756,747, 5,395,937, 4,689,338, EP 385630, WO 97/48704, WO 92/06093 and WO 92/15581, all of which are incorporated by reference in their entirety herein.
  • The invention is also directed to novel 1H-imidazo[4,5-c] quinoline 4-phthalimide intermediates of formula (II), which are useful in preparing 1H-imidazo [4,5-c]quinoline-4-amines of formula (I), and to a process for preparing the intermediates of formula (II).
  • The 1H-imidazo[4,5-c] quinoline 4-phthalimide intermediates of formula (II) are prepared by reacting a 1H-imidazo[4,5-c] quinoline N-oxide of formula (III) with phthalimide. The reaction is carried out in a solvent and a base. Preferred solvents include methylene chloride and ethylacetate. Preferred bases include tri-n-butylamine, triethylamine, and triisobutylamine. The most preferred mixture is ethylacetate and tri-n-butylamine. The reaction is preferably carried out in the presence of an organic acid halide, such as, benzoyl chloride. The reaction is preferably carried out at a temperature of between about 0-10° C., over a period of about one hour.
  • The 1H-imidazo[4,5-c] quinoline N-oxides of formula (III) can be obtained by any method known in the art, including those disclosed in: U.S. Pat. No. 5,756,747, WO 92/06093 and WO 92/15581, all of which are incorporated by reference in their entirety herein.
  • The 1H-imidazo[4,5-c] quinoline 4-phthalimide intermediates of formula (II) are then reacted with hydrazine hydrate in a suitable solvent to form 1H-imidazo[4,5-c] quinoline-4-amines of formula (I). Water is a preferred solvent. Preferably, isooctyl alcohol is added to avoid foam formation. The reaction is preferably carried out at a temperature of between about 94-95° C., over a period of about 4-5 hours.
  • One reaction scheme that may be used to make 1H-imidazo[4,5-c]quinoline-4-amines of formula (I) is shown below:
    Figure US20070060755A1-20070315-C00005
  • The present invention is illustrated in further detail with reference to the following non-limiting examples.
  • EXAMPLE 1 Preparation of 4-isobutyl-3-nitro quinoline
  • 4-chloro-3-nitro-quinoline is reacted with isobutyl amine in the presence of triethylamine (TEA) at between −10 and +15° C. in toluene, while excluding moisture. After washing and phase separation, the organic solution is ready for the next step.
  • EXAMPLE 2 Preparation of 4-isobutyl-3-amino quinoline
  • The nitroxide group on the 4-isobutyl-3-nitro quinoline produced in Example 1 is reduced by catalytic reduction using toluene as solvent, Pd/C 5% (50% wet) as catalyst, at 40-45° C. and atmospheric pressure to produce 4-isobutyl-3-amino quinoline. The rate of reaction depends on efficiency of stirring. After catalyst filtration the solution is ready for the next step.
  • EXAMPLE 3 Preparation of 1-isobutyl-1H-imidazo[4,5-c]quinoline
  • The cyclization of 4-isobutyl-3-amino quinoline produced in Example 2 is carried out in toluene at 102-110° C. using TEOF (triethyl orthoformate) and 20% moles of formic acid to increase the rate of reaction, to produce 1-isobutyl-1H-imidazo[4,5-c]quinoline. Before addition of TEOF, in order to prevent its hydrolysis, it is necessary to remove water formed during the catalytic reduction by azeotropic distillation. A mixture of ethanol and toluene is distilled during the reaction to maintain the internal temperature at 102-110° C.
  • EXAMPLE 4
  • Preparation of 1-isobutyl-1H-imidazo[4,5-c]N-oxide
  • The oxidation of 1-isobutyl:1H-imidazo[4,5-c]quinoline produced in Example 3 is carried out in toluene at 40-45 248C using peracetic acid as oxidant to produce 1-isobutyl-1H-imidazo[4,5-c]N-oxide. The product is isolated by filtration after addition of a sodium sulfate solution and ammonium hydroxide.
  • EXAMPLE 5 Preparation of 1-isobutyl-1H-imidazo[4,5-c]quinoline-4-phthalimide
  • 93 ml of methylene chloride and 15 g of 1-isobutyl-1H-imidazo[4,5-c] quinoline N-oxide (HPLC=95%) are loaded into a 250 ml three necked round flask. Then 24.55 g of tri n-butylamine (98%) and 10.06 g of phthalimide (99%) are added to the flask under nitrogen and stirring. The suspension formed is cooled to 0° C. and the following solution is dropped into the suspension over 1 hour: 12.7 g of benzoyl chloride (98%) in 13 ml of methylene chloride, as the temperature is kept between 0-10° C. The mixture is stirred at room temperature for about 30 minutes and a sample is taken. HPLC analysis shows that there is 0.32% of the starting material, 87.72% of the target product, and 0.43% of the 4-hydroxy derivative. The solution is filtered and the filter cake is washed 3 times with 10 ml of methylene chloride. The wet filter cake is resuspended at 25° C. for at least 7 hours in 100 ml of methanol. After resuspension, the solution is filtered and the filter cake is washed 2 times with 10 ml of methanol. Prior to the second filtration, HPLC shows that there is ≦0.4% of the starting material and ≦0.05% of the 4-hydroxy derivative. The solid is dried under vacuum at 50° C. for 15 hours. The dry solid weighs 18 g. HPLC analysis shows that the solid is 98.98% pure and the yield is 81.52% based on the starting material (1-isobutyl-1H-imidazo[4,5-c]quinoline N-oxide).
  • EXAMPLE 6 Preparation of 1-isobutyl-1H-imidazo[4,5-c]quinoline-4-amine
  • 72 ml water and 18 g 1-isobutyl-1H-imidazo[4,5-c]quinoline-4-phthalimide (HPLC=98.98%) are heated to 70° C. in a 250 ml reactor. 4.8 g hydrazine hydrate is dropped into the reactor while stirring and then 2 ml iso-octyl alcohol is added to the reactor. The reaction mixture is heated at 94-95° C. for 4 hours and a sample is taken. HPLC analysis shows that there is 6.16% starting material and 94 % target material. To obtain a complete conversion of starting material the reaction is allowed to proceed for another hour. The reaction mixture is cooled at 60° C. and 180 ml of methanol is added. The mixture is warmed at reflux for 15 minutes, then cooled at room temperature. The solution is filtered and the cake is washed 3 times with 15 ml of a 3.5:1 mixture of methanol and water. The wet solid obtained weighs 22.4 g. HPLC analysis shows that its purity is 98.23% (no phthalhydrazide integration). The wet solid is treated with 180 ml of water and 5.2 g of 37% HCl at 90-93° C. for 30 minutes. The hot suspension is filtered and the cake is washed 3 times with 15 ml of water. The solid is phthalhydrazide weighing 4.5 g. The hot solution is treated at 90-93° C. with 0.115 g Na2S2O4 and 0.576 g charcoal. After 30 minutes the charcoal is filtered off and the cake is washed two times with 10 ml water. The solution is cooled at 70-75° C. and 10 g of 30% NaOH is added to pH 11.54, at which time a solid precipitates. The mixture is cooled to room temperature and after 1 hour the solid is filtered and the cake is washed 3 times with 10 ml water. 15.1 g of crude wet Imiquimod (pale pink color) is obtained. The Imiquimod is dried to a weight of 10.57 g. HPLC shows the purity to be 98.12%. There is 1.55% phthalhydrazide present.
  • EXAMPLE 7 Purification of 1-isobutyl-1H-imidazo[4,5-c]quinoline-4-amine
  • 53.55 ml water, 23.62 ml butyl alcohol, 10.57 crude Imiquimod, and 4.77 g of 37% HCl are loaded into a 100 ml reactor. The mixture is heated to 55-60° C. to obtain a solution. The solution is cooled to room temperature and a white crystal precipitates. The solid is filtered and washed 2 times with 5 ml butyl alcohol. 13.63 g of wet Imiquimod chloridrate is obtained. HPLC analysis shows that there is 99.89% Imiquimod and 0.01% phthalhydrazide. 120 ml water and 13.63 g of wet Imiquimod chloridate are loaded into a 250 ml reactor and heated to 85-90° C. The hot solution is filtered and the cake is washed with 5 ml of hot water. Then 0.024 g of Na2S2O4 is added. The colorless solution is cooled to 70-75° C. and 5.3 g of 30% NaOH is added to provide a pH of 9.7, at which point a solid precipitates. The suspension is cooled to 20° C. and filtered. The cake is washed 3 times with 5 ml water and twice with 5 ml methanol. During the washes no chloride was detected by silver nitrate. The solid is dried under vacuum at 50° C. for 8 hours. 8.98 g of Imiquimod (off-white color) is obtained. HPLC shows the purity to be 99.94% and the yield to be 63.3% based on the starting material (1-isobutyl-1H-imidazo[4,5-c]quinoline N-oxide).
  • Having thus described the invention with reference to particular preferred embodiments and illustrated it with examples, those of skill in the art may appreciate modifications to the invention as described and illustrated that do not depart from the spirit and scope of the invention as disclosed in the specification.

Claims (4)

1. A process for preparing a compound of formula (I):
Figure US20070060755A1-20070315-C00006
comprising:
a) preparing a compound of formula (II):
Figure US20070060755A1-20070315-C00007
and
b) reacting the compound of formula (II) with hydrazine hydrate to form a compound of formula (I), wherein
R1 is selected from the group consisting of hydrogen; a straight or branched chain alkyl of one to about 10 carbon atoms, optionally substituted with a substituent selected from the group consisting of lower alkyl, cycloalkyl of 3 to about 6 carbon atoms, wherein said cycloalkyl is optionally substituted with a lower alkyl group; straight or branched chain alkenyl of 2 to about 10 carbon atoms, wherein the olefinic unsaturation in the alkenyl group is at least one carbon atom removed from the 1-nitrogen, and wherein the straight or branched chain alkyl is optionally substituted with a substituent selected from the group consisting of lower alkyl, cycloalkyl of 3 to about 6 carbon atoms, wherein said cycloalkyl is optionally substituted with a lower alkyl group; hydroxyalkyl of one to about six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or benzoyloxy and the alkyl moiety contains one to about six carbon atoms; benzyl; (phenyl)ethyl; and phenyl, wherein said benzyl, (phenyl)ethyl and phenyl substituents are optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain more than 6 carbon atoms;
R2 is selected from the group consisting of: hydrogen; straight or branched chain alkyl containing one to about eight carbon atoms; benzyl; (phenyl)ethyl; and phenyl, wherein said benzyl, (phenyl)ethyl and phenyl substituents are optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain more than 6 carbon atoms;
R is independently selected from the group consisting of alkoxy of one to about four carbon atoms; alkyl of one to about four carbon atoms; and halogen; and
n is an integer from 0 to 2, with the proviso that if n is 2, then said groups together contain no more than 6 carbon atoms.
2. The process of claim 1, wherein R, is isobutyl, R, is hydrogen, and n is 0.
3. The process of claim 1, wherein the compound of formula (II) is prepared by reacting a compound of formula (III):
Figure US20070060755A1-20070315-C00008
with phthalimide.
4. The process of claim 3, wherein R1 is isobutyl, R2 is hydrogen, and n is 0.
US11/600,673 2002-07-23 2006-11-15 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates Abandoned US20070060755A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/600,673 US20070060755A1 (en) 2002-07-23 2006-11-15 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39760702P 2002-07-23 2002-07-23
US10/626,036 US6852861B2 (en) 2002-07-23 2003-07-23 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates
US11/023,021 US7153967B2 (en) 2002-07-23 2004-12-23 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates
US11/600,673 US20070060755A1 (en) 2002-07-23 2006-11-15 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/023,021 Division US7153967B2 (en) 2002-07-23 2004-12-23 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates

Publications (1)

Publication Number Publication Date
US20070060755A1 true US20070060755A1 (en) 2007-03-15

Family

ID=30771087

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/626,036 Expired - Fee Related US6852861B2 (en) 2002-07-23 2003-07-23 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates
US11/023,021 Expired - Fee Related US7153967B2 (en) 2002-07-23 2004-12-23 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates
US11/600,673 Abandoned US20070060755A1 (en) 2002-07-23 2006-11-15 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/626,036 Expired - Fee Related US6852861B2 (en) 2002-07-23 2003-07-23 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates
US11/023,021 Expired - Fee Related US7153967B2 (en) 2002-07-23 2004-12-23 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates

Country Status (17)

Country Link
US (3) US6852861B2 (en)
EP (1) EP1543002B1 (en)
JP (1) JP2006502121A (en)
KR (1) KR20050028047A (en)
CN (1) CN1315828C (en)
AT (1) ATE338044T1 (en)
AU (1) AU2003259226A1 (en)
CA (1) CA2493227A1 (en)
DE (1) DE60308040T2 (en)
DK (1) DK1543002T3 (en)
ES (1) ES2271650T3 (en)
HR (1) HRP20050159A2 (en)
IL (1) IL166309A (en)
MX (1) MXPA05000893A (en)
PL (1) PL374884A1 (en)
PT (1) PT1543002E (en)
WO (1) WO2004009593A1 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
MXPA04012199A (en) 2002-06-07 2005-02-25 3M Innovative Properties Co Ether substituted imidazopyridines.
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US20040214851A1 (en) * 2003-04-28 2004-10-28 3M Innovative Properties Company Compositions and methods for induction of opioid receptors
TW200510412A (en) * 2003-08-12 2005-03-16 3M Innovative Properties Co Oxime substituted imidazo-containing compounds
CA2535338C (en) * 2003-08-14 2013-05-28 3M Innovative Properties Company Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
CA2536136C (en) * 2003-08-27 2012-10-30 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
JP2007504269A (en) 2003-09-05 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Method for treating CD5 + B cell lymphoma
WO2005033049A2 (en) 2003-10-01 2005-04-14 Taro Pharmaceuticals U.S.A., Inc. METHOD OF PREPARING 4-AMINO-1H-IMIDAZO(4,5-c)QUINOLINES AND ACID ADDITION SALTS THEREOF
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
NZ546274A (en) 2003-10-03 2009-12-24 3M Innovative Properties Co Pyrazolopyridines and analags thereof
JP5043435B2 (en) 2003-10-03 2012-10-10 スリーエム イノベイティブ プロパティズ カンパニー Alkoxy substituted imidazoquinolines
AU2004291122A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
CN1906193A (en) * 2003-11-14 2007-01-31 3M创新有限公司 Oxime substituted imidazo ring compounds
EP1686992A4 (en) * 2003-11-25 2009-11-04 3M Innovative Properties Co Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
AR046781A1 (en) 2003-11-25 2005-12-21 3M Innovative Properties Co IMIDAZOQUINOLINE DERIVATIVES. PHARMACEUTICAL COMPOSITIONS.
WO2005076783A2 (en) * 2003-12-04 2005-08-25 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
CA2552101A1 (en) * 2003-12-29 2005-07-21 3M Innovative Properties Company Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
WO2005066170A1 (en) * 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
WO2005066169A2 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
WO2005094531A2 (en) * 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US7897609B2 (en) * 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006009826A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
EP1765348B1 (en) * 2004-06-18 2016-08-03 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US20090270443A1 (en) * 2004-09-02 2009-10-29 Doris Stoermer 1-amino imidazo-containing compounds and methods
AU2005282726B2 (en) * 2004-09-02 2011-06-02 3M Innovative Properties Company 1-alkoxy 1H-imidazo ring systems and methods
AU2005282523A1 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1H imidazo ring systems and methods
JP2008515928A (en) * 2004-10-08 2008-05-15 スリーエム イノベイティブ プロパティズ カンパニー Adjuvants for DNA vaccines
WO2006063072A2 (en) * 2004-12-08 2006-06-15 3M Innovative Properties Company Immunomodulatory compositions, combinations and methods
EP1831214A1 (en) * 2004-12-27 2007-09-12 Usv Limited A process for preparation of 4-amino-1-isobutyl-1h-imidazo[4,5-c]-quinoline (imiquimod)
CA2592897A1 (en) * 2004-12-30 2006-07-13 Takeda Pharmaceutical Company Limited 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
JP2008526765A (en) * 2004-12-30 2008-07-24 スリーエム イノベイティブ プロパティズ カンパニー Treatment of skin metastases
WO2006074003A2 (en) * 2004-12-30 2006-07-13 3M Innovative Properties Company CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS
US8034938B2 (en) 2004-12-30 2011-10-11 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
WO2006084251A2 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
AU2006212765B2 (en) 2005-02-09 2012-02-02 3M Innovative Properties Company Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
AU2006338521A1 (en) 2005-02-09 2007-10-11 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
CA2597446A1 (en) * 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
JP2008530113A (en) 2005-02-11 2008-08-07 コーリー ファーマシューティカル グループ,インコーポレイテッド Oxime and hydroxyramine substituted imidazo [4,5-c] ring compounds and methods
US8178677B2 (en) * 2005-02-23 2012-05-15 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
JP2008531567A (en) * 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ,インコーポレイテッド Hydroxyalkyl-substituted imidazoquinoline compounds and methods
AU2006216799A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
AU2006216686A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
JP2008539252A (en) * 2005-04-25 2008-11-13 スリーエム イノベイティブ プロパティズ カンパニー Immune activation composition
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
EA200800782A1 (en) * 2005-09-09 2008-08-29 Коли Фармасьютикал Груп, Инк. AMIDA AND CARBAMATE DERIVATIVES N- {2- [4-AMINO-2- (ETOXIMETHYL) -1H-IMIDAZOLO [4,5-c] QUINOLIN-1-IL] -1,1-DIMETHYLETHYL} METHANE SULFONAMIDE AND METHODS
JP5247458B2 (en) 2005-11-04 2013-07-24 スリーエム・イノベイティブ・プロパティーズ・カンパニー Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
WO2007100634A2 (en) 2006-02-22 2007-09-07 3M Innovative Properties Company Immune response modifier conjugates
WO2007106854A2 (en) * 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
US8178539B2 (en) * 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
EP1966205A2 (en) * 2006-10-16 2008-09-10 Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság Preparation of 1h-imidazo[4,5-c]quinolin-4-amines via 1h-imidazo[4,5-c]quinolin-4-phthalimide intermediates
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
HUE033901T2 (en) 2010-08-17 2018-01-29 3M Innovative Properties Co Lipidated immune response modifier compound compositions, formulations, and methods
JP6460789B2 (en) 2011-06-03 2019-01-30 スリーエム イノベイティブ プロパティズ カンパニー Heterobifunctional linker having polyethylene glycol segment and immune response modulating complex prepared from the linker
BR112013031039B1 (en) 2011-06-03 2020-04-28 3M Innovative Properties Co hydrazine compounds 1h-imidazoquinoline-4-amines, conjugates made from these compounds, composition and pharmaceutical composition comprising said compounds and conjugates, uses thereof and method of manufacturing the conjugate
EP3728255B1 (en) 2017-12-20 2022-01-26 3M Innovative Properties Company Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689388A (en) * 1985-01-24 1987-08-25 Ajinomoto Co., Inc. One pack type alicyclic epoxy resin compositions
US4689338A (en) * 1983-11-18 1987-08-25 Riker Laboratories, Inc. 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use
US4698348A (en) * 1983-11-18 1987-10-06 Riker Laboratories, Inc. 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents
US4988815A (en) * 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5367076A (en) * 1990-10-05 1994-11-22 Minnesota Mining And Manufacturing Company Process for imidazo[4,5-C]quinolin-4-amines
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5756747A (en) * 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1271477A (en) 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
DE3854476T2 (en) * 1987-07-06 1996-04-04 Univ Louisiana State INHIBITATION OF EUKARYOTIC PATHOGENES AND NEOPLASMS WITH LYTIC PEPTIDES.
DK0385630T3 (en) 1989-02-27 1997-05-12 Riker Laboratories Inc 1H-imidazo (4,5-c) quinoline-4-amines as antivirals
DE4005874A1 (en) * 1990-02-24 1991-11-07 Boehringer Mannheim Gmbh CARRIER-TIED RECOMBINANT PROTEINS, METHOD FOR THE PRODUCTION AND USE AS IMMUNOGENIC AND VACCINE
JP2941413B2 (en) 1990-11-28 1999-08-25 ライカー ラボラトリース インコーポレーテッド Method for producing 1H-imidazo [4,5-c] quinolines
DK0872478T3 (en) * 1991-03-01 2003-03-31 Minnesota Mining & Mfg Intermediates for the preparation of 1-substituted, 2-substituted 1H-imidazo [4,5-c] quinoline-4-amines
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
JP5006500B2 (en) * 2000-08-16 2012-08-22 ザ・ボーイング・カンパニー Method and apparatus for providing interactive data services and live broadcast television programs to mobile platforms

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689338A (en) * 1983-11-18 1987-08-25 Riker Laboratories, Inc. 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use
US4698348A (en) * 1983-11-18 1987-10-06 Riker Laboratories, Inc. 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents
US4689388A (en) * 1985-01-24 1987-08-25 Ajinomoto Co., Inc. One pack type alicyclic epoxy resin compositions
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5756747A (en) * 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US4988815A (en) * 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5578727A (en) * 1989-10-26 1996-11-26 Riker Laboratories, Inc. Process for 1H-imidazo[4,5-c]quinolines
US5602256A (en) * 1989-10-26 1997-02-11 Riker Laboratories, Inc. Process for 1H-imidazo[4,5-C]quinolines
US5367076A (en) * 1990-10-05 1994-11-22 Minnesota Mining And Manufacturing Company Process for imidazo[4,5-C]quinolin-4-amines
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines

Also Published As

Publication number Publication date
CA2493227A1 (en) 2004-01-29
KR20050028047A (en) 2005-03-21
US7153967B2 (en) 2006-12-26
IL166309A (en) 2010-04-15
MXPA05000893A (en) 2005-09-30
IL166309A0 (en) 2006-01-15
EP1543002B1 (en) 2006-08-30
EP1543002A1 (en) 2005-06-22
ATE338044T1 (en) 2006-09-15
US20050113404A1 (en) 2005-05-26
PL374884A1 (en) 2005-11-14
DK1543002T3 (en) 2006-12-27
WO2004009593A1 (en) 2004-01-29
US6852861B2 (en) 2005-02-08
PT1543002E (en) 2006-11-30
ES2271650T3 (en) 2007-04-16
DE60308040T2 (en) 2007-04-19
JP2006502121A (en) 2006-01-19
US20040138459A1 (en) 2004-07-15
DE60308040D1 (en) 2006-10-12
CN1315828C (en) 2007-05-16
AU2003259226A1 (en) 2004-02-09
CN1681814A (en) 2005-10-12
HRP20050159A2 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
US6852861B2 (en) Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates
US7166721B2 (en) Preparation of 1H-imidazo[4,5-C] quinolin 4-amines via novel 1H-imidazo[4,5-c] quinolin 4-cyano and 1H-imidazo[4,5-c] quinolin 4-carboxamide intermediates
JP3315983B2 (en) 1-substituted 1H-imidazo (4,5-c) quinolin-4-amines, intermediates and pharmaceutical compositions
WO2014005443A1 (en) Method for preparing selective anticoagulant ticagrelor and the intermediate thereof
US6184380B1 (en) Process for preparing naphthyridones and intermediates
US7232907B2 (en) Process for production of naphthyridine-3-carboxylic acid derivatives
CZ110398A3 (en) Process for preparing antimalarial substances
CA2445766A1 (en) Improved process for preparing zolpidem
WO2006035452A1 (en) Novel pseudomorph of valaciclovir hydrochloride
EP0930297B1 (en) A process for preparing naphthyridones and intermediates
US7019142B2 (en) Process for preparing naphthyridones and intermediates
TW202333684A (en) The method of the preparation of fused multicyclic compounds
US20080103310A1 (en) Preparation of 1H-imidazo[4,5-c]quinolin-4-amines via 1H-imidazo[4, 5-c]quinolin-4-phtalimide intermediates
CZ288287B6 (en) Process for preparing 5-(alkoxymethyl)-2,3-pyridine dicarboximide compounds
WO2008048683A2 (en) Preparation of 1h-imidazo[4,5-c]quinolin-4-amines via 1h-imidazo[4,5-c]quinolin-4-phthalimide intermediates
CZ11999A3 (en) Process for preparing naphthyridones and intermediates for such preparation process

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION